The fight against breast cancer is taking a positive turn, fueled by advancements in early detection methods. A recent study by Future Market Insights (FMI) on the Breast Cancer Screening Tests Market paints a promising picture, predicting a Compound Annual Growth Rate (CAGR) of 7.8% from 2022 to 2033. This translates to a significant market expansion, with the value expected to climb from USD 1.9 billion in 2022 to a remarkable USD 4.4 billion by 2033.
Globally, digital mammography has supplanted traditional film-based mammography. Digital mammography has advantages such as improved image quality, quicker image storage and retrieval, and the possibility of computer-aided detection (CAD) systems assisting radiologists in interpretation.
Imaging technologies, such as 3D mammography (tomosynthesis), have advanced in the breast cancer screening test market, providing more comprehensive images and reducing false-positive findings. Other developing technologies are being investigated for improved accuracy and patient experience, such as contrast-enhanced mammography and automated breast ultrasonography.
Stay Informed With The Latest Trends, Projections, And Advancements In Breast Cancer Screening Technologies, Helping You Make Informed Decisions In This Critical Healthcare Sector. Get Our Sample Report Now!
Biomarker testing, in addition to imaging-based screening assays, is significant in breast cancer screening. Biomarkers, such as BRCA gene mutations and specific protein markers (e.g., HER2, hormone receptors), aid in determining a person’s risk of getting breast cancer and guiding treatment recommendations.
Regulatory agencies, such as the United States Food and Drug Administration (FDA), are critical in authorizing and regulating breast cancer screening tests to assure their safety and efficacy. Compliance with regulatory regulations is required for screening test market entry and commercialization.
Key Takeaways from the Breast Cancer Screening Tests Market:
- Among diagnostic test types, imaging tests account for USD 1.1 billion in 2022, owing to their potential for computer-aided detection (CAD) systems to assist radiologists in interpretation.
- Hospitals held more than 42.3% of the global market share in 2022. This can be attributed to the fact that the majority of the world’s population suffers from diseases that, with skilled assistance, can be appropriately detected in the hospital setting.
- By region, North American Breast Cancer Screening Tests Market held the dominant share in the world in 2022. The U.S. leads in this region with a high prevalence of breast cancer and a high requirement for breast cancer screening devices.
- East Asia is set to provide lucrative opportunities for players while growing at an expected growth rate of 10.5% CAGR over the forecast period.
“The growing cancer burden and increasing adoption of non-invasive treatment contribute to higher demand of breast cancer screening tests.” says an analyst of Future Market Insights.
Announces New Strategies to Thrive in Intense Market Competition:
The breast cancer screening test market is highly competitive, with key players including Ion Beam and Sumitomo Heavy Industries. These companies are constantly participating in partnerships, award competition with their products, and launching new products to gain a larger market share, focusing on affordability, convenience, and effectiveness.
- In June 2023, Heligenics, a cutting-edge biotech startup, announced the development of the first precise genetic test for choosing among breast cancer medicines.
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
- Siemens Healthineers
- Hologic Inc.
- General Electric Company
- Koninklijke Philips NV
- Fujifilm Holdings
- A&G Pharmaceutical, Inc.
- Biocrates Life Sciences AG
- Metabolomic Technologies, Inc.
- Myriad Genetics
- OncoCyte Corporation
- POC Medical Systems, Inc.
- Hologic, Inc.
- Provista Diagnostics, Inc.
- BioTime, Inc.
To access the secrets of the Competition Dashboard and delve into the mystical realm of Branding and Promotional Strategies. Purchase now to harness unparalleled strategic insights!
Global Breast Cancer Screening Tests Market: Historical Analysis and Projections for 2023-2033
Future Market Insights offers a unique perspective and actionable insights on the breast cancer screening tests market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global breast cancer screening tests market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
The analysis is based on diagnostic test type (blood marker tests, imaging tests (mammography, MRI screening test, molecular breast imaging test, PET scan, ultrasound), genetic test (Fluorescence In Situ Hybridization and HER gene test), and immunohistochemistry tests), and end-user (hospitals, diagnostics centers, cancer institutes, research laboratories), across seven key regions around the world.
Key Market Segments Covered in the Breast Cancer Screening Test Market Research:
By Diagnostics Test Type:
- Blood Marker Tests
- Imaging Test
- Mammography
- MRI screening test
- Molecular Breast Imaging Test
- PET scan
- Ultrasound
- Genetic Test
- Fluorescence In Situ Hybridization
- HER gene test
- Immunohistochemistry Test
By End User:
- Hospitals
- Diagnostic Centres
- Cancer Institutes
- Research Laboratories
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Covering Every Aspect Of The Market. The Report Provides Detailed Segmentation. To Customize your report connect with our Research Analyst and avail of the special discount!
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments based on Source, Application, Sales Channel, and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube